search
Back to results

Transcutaneous Partial Oxygen and Carbon Dioxide Pressures Compared With Blood Gas Values (OxiVenT)

Primary Purpose

Critical Illness

Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Sentec (SenTec) Digital Monitoring System with OxiVenT Sensor
Sponsored by
Vera Bernet, MD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Critical Illness

Eligibility Criteria

undefined - 10 Weeks (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Late premature or term birth newborn infants (34 0/7 until 43 6/7 weeks gestational age (GA)).
  • Age between first day of life and 43 6/7 weeks postmenstrual age.
  • Ability of care taker to understand verbal and written instructions and informed consent in German.

Exclusion Criteria:

  • Care taker unable or unwilling to give written informed consent in German.
  • Care taker not understanding German and without a family member able to translate.
  • Written informed consent cannot be obtained for any other reason.

Sites / Locations

  • University Children's Hospital Zurich

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

All included patients

Arm Description

All included patients will undergo the intervention of transcutaneous sensor placement

Outcomes

Primary Outcome Measures

Bias and precision of the transcutaneous oxygen and carbon dioxide measurements
Agreement of transcutaneous measurements with capillary and arterial blood gas values at two operational sensor temperatures (42 and 43°C).

Secondary Outcome Measures

Agreement of partial transcutaneous oxygen and carbon dioxide pressures with arterial and capillary values in children with echocardiographically determined congenital cyanotic heart disease and/or intra or extra cardiac right to left shunt
Bias and precision of oxygen and carbon dioxide transcutaneous measurements under the influence of vasoactive drugs (Adrenalin, Noradrenalin, Dopamine, Dobutamine, Vasopressin, Milrinone)
Bias and precision of oxygen and carbon dioxide transcutaneous measurements under the influence of elevated indirect bilirubin
Bias and precision of the oxygen and carbon dioxide transcutaneous measurements over time at one anatomical site with determination of technical drift and physiological drift
Bias and precision of transcutaneous partial oxygen and carbon dioxide pressure measurements in patients with skin and soft tissue oedema
Bias and precision of transcutaneous partial oxygen and carbon dioxide pressure measurements with changing peripheral perfusion
Bias and precision of transcutaneous partial oxygen and carbon dioxide pressure measurements with different skin colour types
Safety of OxiVenT sensor: Appearance of signs of thermal injury (redness, blisters, necrosis) under application of transcutaneous sensor temperatures of 42 and 43°C
While operated at sensor temperatures of 42 and 43°C, the skin will be closely observed for any kind of thermic tissue damage

Full Information

First Posted
February 11, 2017
Last Updated
February 4, 2019
Sponsor
Vera Bernet, MD
search

1. Study Identification

Unique Protocol Identification Number
NCT03060018
Brief Title
Transcutaneous Partial Oxygen and Carbon Dioxide Pressures Compared With Blood Gas Values
Acronym
OxiVenT
Official Title
Agreement of Transcutaneous Partial Oxygen and Carbon Dioxide Pressure With Arterial and Capillary Blood Gas Values. A Single Centre Prospective Non-randomized Trial in Critically Ill Neonates.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
August 17, 2017 (Actual)
Primary Completion Date
December 31, 2018 (Actual)
Study Completion Date
December 31, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Vera Bernet, MD

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Partial blood oxygen and carbon dioxide pressures obtained in critical ill neonates by transcutaneous sensors will be compared to respective values obtained by medically indicated arterial and capillary blood gas analyses. The influence of blood withdrawal method, sensor operational temperature and application time, presence of cyanotic heart malformations and/or intra or extra cardiac right to left shunt, vasoactive drugs, elevated non-conjugated bilirubin, and skin and soft tissue oedema, skin colour and perfusion conditions will be elucidated as well as sensor's safety. Study duration will be 48 hours with sensors applied and additional 4 hours of further surveillance for thermal injury.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critical Illness

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
113 (Actual)

8. Arms, Groups, and Interventions

Arm Title
All included patients
Arm Type
Experimental
Arm Description
All included patients will undergo the intervention of transcutaneous sensor placement
Intervention Type
Device
Intervention Name(s)
Sentec (SenTec) Digital Monitoring System with OxiVenT Sensor
Intervention Description
The sensor will be attached to four anatomical positions (thoracic left and right; abdominal left and right), starting with the left thoracic position followed by 4-hourly clockwise position rotation. In case of severe oedema, the ear lobes will be used as anatomical measurement sites and changes to the contralateral ear lobe are made every 4 hours.
Primary Outcome Measure Information:
Title
Bias and precision of the transcutaneous oxygen and carbon dioxide measurements
Description
Agreement of transcutaneous measurements with capillary and arterial blood gas values at two operational sensor temperatures (42 and 43°C).
Time Frame
52 hours
Secondary Outcome Measure Information:
Title
Agreement of partial transcutaneous oxygen and carbon dioxide pressures with arterial and capillary values in children with echocardiographically determined congenital cyanotic heart disease and/or intra or extra cardiac right to left shunt
Time Frame
52 hours
Title
Bias and precision of oxygen and carbon dioxide transcutaneous measurements under the influence of vasoactive drugs (Adrenalin, Noradrenalin, Dopamine, Dobutamine, Vasopressin, Milrinone)
Time Frame
52 hours
Title
Bias and precision of oxygen and carbon dioxide transcutaneous measurements under the influence of elevated indirect bilirubin
Time Frame
52 hours
Title
Bias and precision of the oxygen and carbon dioxide transcutaneous measurements over time at one anatomical site with determination of technical drift and physiological drift
Time Frame
52 hours
Title
Bias and precision of transcutaneous partial oxygen and carbon dioxide pressure measurements in patients with skin and soft tissue oedema
Time Frame
52 hours
Title
Bias and precision of transcutaneous partial oxygen and carbon dioxide pressure measurements with changing peripheral perfusion
Time Frame
52 hours
Title
Bias and precision of transcutaneous partial oxygen and carbon dioxide pressure measurements with different skin colour types
Time Frame
52 hours
Title
Safety of OxiVenT sensor: Appearance of signs of thermal injury (redness, blisters, necrosis) under application of transcutaneous sensor temperatures of 42 and 43°C
Description
While operated at sensor temperatures of 42 and 43°C, the skin will be closely observed for any kind of thermic tissue damage
Time Frame
52 hours

10. Eligibility

Sex
All
Maximum Age & Unit of Time
10 Weeks
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Late premature or term birth newborn infants (34 0/7 until 43 6/7 weeks gestational age (GA)). Age between first day of life and 43 6/7 weeks postmenstrual age. Ability of care taker to understand verbal and written instructions and informed consent in German. Exclusion Criteria: Care taker unable or unwilling to give written informed consent in German. Care taker not understanding German and without a family member able to translate. Written informed consent cannot be obtained for any other reason.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vera Bernet, Prof, MD
Organizational Affiliation
University of Zurich
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Children's Hospital Zurich
City
Zürich
ZIP/Postal Code
8032
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35124680
Citation
Baumann P, Gotta V, Adzikah S, Bernet V. Accuracy of a Novel Transcutaneous PCO2 and PO2 Sensor with Optical PO2 Measurement in Neonatal Intensive Care: A Single-Centre Prospective Clinical Trial. Neonatology. 2022;119(2):230-237. doi: 10.1159/000521809. Epub 2022 Feb 4.
Results Reference
derived

Learn more about this trial

Transcutaneous Partial Oxygen and Carbon Dioxide Pressures Compared With Blood Gas Values

We'll reach out to this number within 24 hrs